Updates from Neoclease, awards, partnerships, and press mentions from the team building our nuclease platform.
Neoclease has been selected for the Drive Fall 2026 cohort, the startup program run by MassBio and SCbio, joining nine other emerging techbio and biotech teams for eight weeks of mentorship ahead of the Align Summit in Boston on October 15.
Neoclease has graduated from Creative Destruction Lab's (CDL) Advanced Therapies program, completing every objective-setting session in one of deep tech's most selective venture programs.
Neoclease was featured in the Boston Business Journal as part of a growing wave of AI-native biotech startups, in an article exploring AI as a foundational engine for discovery, platform development, and therapeutic innovation.
Neoclease joined the inaugural LabCentral AI BioHub, created with C10 Labs, an accelerator bringing together founders, mentors, and technical talent to tackle life-sciences challenges through sessions on AI-driven innovation and commercialization, capped by a two-day hackathon.
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, named Neoclease winner of its 2025 North American Advance Biotech Grant, providing access to M Lab™ Collaboration Center resources to advance our lead candidate, NCX-L2, for Parkinson's disease.
Following a pitch by CEO & Co-Founder Chelsea Trengrove, Ph.D. at the Aging Code Summit, Neoclease was awarded a one-year residency at The Engine, the MIT-founded venture firm supporting "tough tech" startups.